HOW TO PROVE THAT AGING CAN BE TAMED AND THAT APPROPRIATE REGULATION CAN BE FOLLOWED?

The challenge is to have an FDA indication to target aging to allow for healthcare providers to pay for such therapy. Without that pharmaceutical companies will not develop a drug that has no business horizon. To make a proof of concept in humans, we chose metformin, one drug that targets the biolog...

Full description

Saved in:
Bibliographic Details
Published in:Innovation in aging 2018-11, Vol.2 (suppl_1), p.544-544
Main Author: Barzilai, N
Format: Article
Language:English
Subjects:
Abstracts
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The challenge is to have an FDA indication to target aging to allow for healthcare providers to pay for such therapy. Without that pharmaceutical companies will not develop a drug that has no business horizon. To make a proof of concept in humans, we chose metformin, one drug that targets the biology of aging and extends life- and health-span in animals. It is used for the treatment and delay of type 2 diabetes, with over 60 years of outstanding safety. Metformin use is also associated with lower rates of cancer, CVD, mortality, and cognitive decline. We designed the TAME (Targeting Aging with MEtformin) trial, a placebo controlled, multi-center study in ~3000 elderly with a novel primary outcome of delaying the incidence of a composite of multiple age-related diseases. This study was designed with the FDA and will lead to the development of better next -generation drugs to target aging.
ISSN:2399-5300
2399-5300
DOI:10.1093/geroni/igy023.2008